Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 341.20M | 297.20M | 245.32M | 205.62M | 189.85M | 228.39M |
Gross Profit | 304.52M | 261.80M | 220.10M | 188.06M | 169.67M | 203.06M |
EBITDA | 30.42M | 16.32M | 9.88M | 33.53M | 48.78M | 92.11M |
Net Income | -8.24M | -10.64M | -10.55M | 13.67M | 16.00M | 37.75M |
Balance Sheet | ||||||
Total Assets | 446.26M | 399.99M | 462.85M | 425.80M | 396.90M | 419.12M |
Cash, Cash Equivalents and Short-Term Investments | 128.73M | 167.89M | 213.42M | 207.34M | 191.72M | 205.49M |
Total Debt | 128.33M | 108.42M | 171.54M | 166.69M | 161.59M | 162.22M |
Total Liabilities | 206.71M | 178.92M | 244.07M | 221.16M | 204.19M | 235.39M |
Stockholders Equity | 239.55M | 221.06M | 218.78M | 204.64M | 192.72M | 183.73M |
Cash Flow | ||||||
Free Cash Flow | 30.80M | -2.59M | -18.77M | 20.92M | 20.17M | 74.51M |
Operating Cash Flow | 31.72M | -1.79M | -17.30M | 22.90M | 36.13M | 90.98M |
Investing Cash Flow | 21.37M | 31.62M | -129.39M | 5.32M | ― | ― |
Financing Cash Flow | -10.67M | -34.41M | -1.04M | -4.98M | ― | 65.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $1.05B | ― | -3.40% | ― | 22.68% | 42.45% | |
55 Neutral | $1.21B | ― | -35.74% | ― | ― | -8.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.01B | 174.05 | -23.56% | ― | 22367.80% | -5.15% | |
48 Neutral | $1.07B | ― | -60.98% | ― | 338.45% | -19.64% | |
43 Neutral | $1.08B | ― | -154.81% | ― | 739.42% | 24.90% | |
43 Neutral | $1.40B | ― | -43.82% | ― | ― | -7.33% |
On October 6, 2025, Pharming Group announced an organizational restructuring aimed at accelerating growth by reducing general and administrative expenses. The restructuring involves a 20% reduction in non-commercial and non-medical staff, primarily in the Netherlands, and is expected to decrease annual G&A expenses by 15% or $10 million. The company anticipates incurring one-time restructuring costs of approximately $7 million in the fourth quarter of 2025. This move is part of Pharming’s strategy to optimize capital allocation and enhance its operational efficiency.
On October 1, 2025, Pharming Group announced that the U.S. FDA has accepted and granted Priority Review to its supplemental New Drug Application for leniolisib, aimed at treating children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. This decision, based on positive Phase III study results, marks a significant step for young patients in the U.S. as leniolisib could become the first approved treatment for this age group, potentially altering the disease’s progression and offering new hope to affected families.
On September 10, 2025, Pharming Group N.V. announced its promotion from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective September 22, 2025. This advancement reflects the company’s strong growth momentum and is expected to enhance its visibility and attractiveness to investors, supporting its goal of becoming a leading global rare disease company.
On September 2, 2025, Pharming Group announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard, a seasoned finance executive with over 20 years of experience in the life sciences industry, is expected to strengthen Pharming’s financial leadership as the company continues its growth strategy. His extensive background in financial and operational transformation across multinational organizations is anticipated to support Pharming’s vision of becoming a leading global rare disease company. This strategic appointment follows Pharming’s strong financial performance in the first half of 2025, signaling a commitment to enhancing operational efficiency and sustainable value creation.
On July 31, 2025, Pharming Group reported a 26% increase in total revenues for the second quarter of 2025, driven by significant growth in RUCONEST® and Joenja® sales. The company achieved a positive operating profit of $10.8 million, reversing a loss from the previous year. Pharming raised its full-year revenue guidance and highlighted a study suggesting a potential 100-fold increase in APDS prevalence, which could expand Joenja®’s market. The company also launched Joenja® in the U.K. and submitted a regulatory filing in Japan, while advancing clinical trials for other pipeline products. Pharming is addressing U.S. tariffs but does not expect a material impact on its business.